Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve the functional outcomes of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19, announces that it has decided to implement, from April 2, 2024, a consolidation of actions composing its share capital, at the rate of 1 new share for every 400 held.